What condition are you treating with Cosentyx?
Cosentyx (secukinumab) treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. Alternatives depend on your specific diagnosis—check with your doctor for personalized options based on severity, response, and side effects.
Top biologic alternatives for plaque psoriasis
For moderate-to-severe plaque psoriasis, common switches from Cosentyx include:
- IL-17 inhibitors like Taltz (ixekizumab): Similar mechanism, often faster skin clearance in head-to-head trials.[1]
- IL-23 inhibitors like Tremfya (guselkumab) or Skyrizi (risankizumab): Target a different inflammation pathway, with longer dosing intervals (every 8-12 weeks).[2]
- TNF inhibitors like Humira (adalimumab) or Enbrel (etanercept): Older options, effective but higher infection risk.[3]
| Drug | Dosing | Key Difference from Cosentyx |
|------|--------|-----------------------------|
| Taltz | Every 4 weeks after loading | Clears nails/psoriasis faster in some studies |
| Tremfya | Every 8 weeks | Better for gut inflammation overlap |
| Skyrizi | Every 12 weeks | Highest sustained clearance rates at 1 year[2] |
Alternatives for psoriatic arthritis or axial spondyloarthritis
If joint pain dominates:
- JAK inhibitors like Xeljanz (tofacitinib) or Rinvoq (upadacitinib): Oral pills, avoid injections; approved for PsA but monitor for blood clots.[4]
- BMS-986197 (experimental IL-17): In trials as a potential Cosentyx rival, but not yet available.[5]
- Otezla (apremilast): Oral PDE4 inhibitor for milder PsA, fewer serious risks but less potent.[3]
For ankylosing spondylitis, Cimzia (certolizumab) or Simponi (golimumab) match Cosentyx efficacy in mobility trials.[1]
How do these compare in effectiveness and safety?
Cosentyx clears 75-90% skin in psoriasis patients at 1 year.[2] Taltz edges it on speed (90% clearance by week 12), while IL-23s like Skyrizi lead long-term (80%+ at year 5).[2][6] All carry infection and IBD risks; TNFs have more TB reactivation cases. Cost: Biosimilars for Humira/Enbrel lower prices to $2,000-5,000/month vs. Cosentyx $6,000+ without insurance.[7]
Non-biologic or cheaper options first?
Before biologics:
- Topicals (Dovonex, calcipotriene) or phototherapy for mild psoriasis.
- Methotrexate or cyclosporine for PsA—generics under $100/month, but liver monitoring needed.[3]
- Lifestyle: Weight loss boosts response by 50% in overweight patients.[8]
When to switch and what patients report
Switch if no 75% improvement by week 12-16, per guidelines.[6] Patient forums note injection pain with Cosentyx; Taltz/Skyrizi pens feel easier. IBD history? Avoid IL-17s, pick IL-23s.[1]
Consult your rheumatologist—insurance often requires failing 1-2 alternatives first.
Sources:
[1] NEJM Taltz vs Cosentyx trial
[2] DrugPatentWatch.com - Cosentyx
[3] AAD Biologics Guide
[4] FDA JAK Warnings
[5] ClinicalTrials.gov BMS-986197
[6] AADA Psoriasis Guidelines
[7] GoodRx Pricing
[8] JAMA Weight Loss Study